Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004–2024)
This study provides a robust real-world safety evaluation of ganirelix, with findings corroborated by two independent pharmacovigilance databases. While consistent with clinical observations, the identification of unexpected signals warrants further pharmacoepidemiological investigations to confirm these results.
Authors
- Zhiwei Cui (ORCID: https://orcid.org/0000-0001-8338-4270)
- Fan Zou (ORCID: https://orcid.org/0000-0002-4436-6923)
- Yang Yang (ORCID: https://orcid.org/0000-0001-5171-6226)
- Xiaoshan Feng (ORCID: https://orcid.org/0000-0001-6525-7833)
- Xiaoling Wu (ORCID: https://orcid.org/0000-0003-1822-8452)
Institutions
- Zunyi Medical University (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1186/s40360-025-00920-4
- Citations
- 1
- Primary Topic
- Reproductive Health and Contraception
- Type
- article
- Field-Weighted Citation Impact
- 1.88